Evidence map›Paper›PMID 42895897›Full record

ArticleCancer biology & therapy2026

Sorting nexin 10 promotes triple-negative breast cancer progression through modulating cholesterol biosynthesis via stabilizing SREBP2.

Yinping Guo, Jiahui Li, Wenjie Zhang, Min Xia, Gaohua Liu, Xiaolin Zhong, Yan Yi, Yajun Chen, Jing Zhong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yinping GuoClinical Medical Research Center, Institute of Cancer Research, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Jiahui LiClinical Medical Research Center, Institute of Cancer Research, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Wenjie ZhangClinical Medical Research Center, Institute of Cancer Research, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Min XiaClinical Medical Research Center, Institute of Cancer Research, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Gaohua LiuClinical Medical Research Center, Institute of Cancer Research, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Xiaolin ZhongClinical Medical Research Center, Institute of Cancer Research, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Yan YiClinical Medical Research Center, Institute of Cancer Research, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Yajun ChenDepartment of Metabolism and Endocrinology, the Second Affiliated Hospital of University of South China, Hengyang, Hunan, China.
Jing ZhongClinical Medical Research Center, Institute of Cancer Research, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.ORCID 0000-0003-4593-4897

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTriple-negative breast cancer (TNBC) lacks effective therapeutics in clinical practice. Sorting nexin 10 (SNX10) plays essential roles in various cancers, and the role of SNX10 in TNBC remains unknown. This study investigated the role and action mechanism of SNX10 in TNBC.

methodsUsing the Kaplan-Meier Plotter database and bc-GenExMiner database to analyze the SNX10 expression and clinical significance. Functional assays, including MTT, colony formation, transwell assays, and xenograft experiments, were used to evaluate the role of SNX10 in TNBC. The GeneChip PrimeView Human Gene Expression Array was used to determine the downstream targets and pathways. Cholesterol levels and the expression of enriched cholesterol synthesis genes were detected by Filipin assay, RT-PCR, and Western Blot. The relationship of SNX10 and cholesterol biosynthesis was confirmed using CO-IP and immunofluorescence staining assays.

resultsSNX10 is positively related to poor prognosis of breast cancer and markedly up-regulated in TNBC. Knockdown of SNX10 suppressed cell proliferation, migration, and invasion, and slowed the tumor growth

conclusionSNX10 promoted TNBC progression through the regulation of cholesterol biosynthesis, which was mediated by interaction with SREBP2 and maintenance of its stability. SNX10 may be an effective therapeutic target for TNBC, and our study provides new insights into therapeutic strategies.

Indexed as

CholesterolSorting NexinsSterol Regulatory Element Binding Protein 2Triple Negative Breast NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMiceMice, NudePrognosisCholesterolSorting NexinsSREBF2 protein, humanSterol Regulatory Element Binding Protein 2cancer progressioncholesterol biosynthesisSNX10SREBP2triple-negative breast cancer

Identifiers

PMID42895897
PMCPMC13682392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.